Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people's lives. Aquestive has focused on applying its technology to address unmet patient needs in CNS conditions, including epilepsy. The Company's first proprietary commercial product was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). The Company is also investigating Libervant™ (diazepam buccal film) as a novel, fast-acting, oral rescue treatment for increased bouts of seizure activity.
Aquestive works with patient advocacy organizations to gain insights into patient needs; to provide accurate, timely and helpful information on our products; and to identify and improve resources that support patients and caregivers throughout their treatment journey. We know that strong patient communities are an essential lifeline to individual families seeking better care and outcomes.
The Art of Living with LGS is a community art project that was organized by Aquestive as a way to help families with LGS share advice, inspiration, and experiences with others. The event debuted at the 6th International Family and Professional Conference on Lennox-Gastaut syndrome. Together, the LGS community created not just art, but also the picture of a better life for all those living with LGS.
